文章预览
Tirzepatide for the treatment of metabolic dysfunctionassociated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial Background and aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liverrelated morbidity and mortality. This study evaluated the efficacy and safety of tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like-peptide-1 receptors, in the treatment of non-cirrhotic MASH with significant liver fibrosis. Method: SYNERGY-NASH (NCT04166773) was a multicenter, doubleblind, randomized, placebo (PBO)-controlled Phase 2 dose-finding trial in patients with biopsy-confirmed MASH, stage 2 or 3 fibrosis and a non-alcoholic fatty liver disease activity score (NAS) ≥4. Participants (n = 190) were randomly assigned 1:1:1:1 to receive once-weekly s.c. tirzepatide (5 mg, 10 mg or 15 mg) or PBO for 52 weeks. The primary end point was MASH resolution without wor
………………………………
